Status and progress of apatinib in treatment of malignant tumors
10.3760/cma.j.issn.1006-9801.2018.04.017
- VernacularTitle:阿帕替尼治疗恶性肿瘤的现状和进展
- Author:
Maoxun WANG
1
;
Lulu GUAN
;
Xiaobing CHEN
Author Information
1. 450003,郑州大学附属肿瘤医院肿瘤内科
- Keywords:
Neoplasms;
Apatinib;
Resistance;
Angiogenesis;
Vascular endothelial growth factor receptor-2
- From:
Cancer Research and Clinic
2018;30(4):281-285
- CountryChina
- Language:Chinese
-
Abstract:
In recent years, anti-angiogenic drugs influencing vascular endothelial growth factor receptor (VEGFR) and vascular endothelial growth factor (VEGF) signaling have been widely used in the treatment of malignant tumors. Apatinib is an orally bioavailable small molecule antiangiogenic agent. The CSCO Guide to Gastro-Oncology,published in 2017, lists apatinib as the only targeted drug targeted for third-line treatment of gastric cancer. This review summarizes the recent advances in the structure, mechanisms of action, reversing drug resistance, clinical efficacy, adverse reactions, and biomarkers in various types of malignancies.
